Ligand Pharmaceuticals | LGND - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Agenus USD 6.21M 4.34M 2026-03
Amgen USD 1.72B 134M 2026-06
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
Baxter International USD 735M 7M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Enviri Corporation USD 104.1M 10.81M 2025-12
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 247.47M 208K 2026-06
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Ligand Pharmaceuticals USD 29.12M 8.29M 2026-06
MacroGenics USD 9.71M 1.77M 2026-03
Merck USD 2.89B 219M 2026-06
Pacira USD 91.81M 7.93M 2026-06
Pfizer USD 3.41B 496M 2026-06
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Veracyte USD 55.71M 4.87M 2026-06